Trial watch: dendritic cell vaccination for cancer immunotherapy.

Abstract

Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.

• Authors: Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Abhishek D Garg
• Journal: Oncoimmunology (Oncoimmunology) 2019 Vol. 8 Issue 11 Pg. e1638212 ISSN: 2162-4011 [Print] United States
• PMID: 31646087 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: © 2019 Taylor & Francis Group, LLC.